Evidence map›Paper›PMID 37732461›Full record

ArticleInternational journal of technology assessment in health care2023

Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France.

Tess Martin, Alessandra Guercio, Hélène Besseau, Laure Huot, Pascale Guerre, Jamal Atfeh, Laurent Piazza, Judith Pineau, Brigitte Sabatier, Isabelle Borget and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of technology assessment in health care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Organizational impact in healthcare in France: a decade of insights but chicken and egg situation.International journal of technology assessment in health care · 2026
    Review
  5. Article
  6. Review
  7. The potential of the hospital-based Health Technology Assessment: Results of a world-wide survey.International journal of technology assessment in health care · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tess MartinPharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France.ORCID https://orcid.org/0000-0002-1839-4306
Alessandra GuercioPharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France.
Hélène BesseauFaculty of Pharmacy, Paris-Saclay University, GRADES, Orsay, France.
Laure HuotHospices Civils de Lyon, Pôle de Santé Publique, Service Evaluation Economique en santé, Lyon, France.ORCID https://orcid.org/0000-0002-7870-9912
Pascale GuerreHospices Civils de Lyon, Pôle de Santé Publique, Service Evaluation Economique en santé, Lyon, France.ORCID https://orcid.org/0000-0002-8182-1227
Jamal AtfehHospices Civils de Lyon, Pôle de Santé Publique, Service Evaluation Economique en santé, Lyon, France.
Laurent PiazzaHealth Economics Unit, Clinical Research Department, Bordeaux University Hospital, Talence, France.
Judith PineauPharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France.
Brigitte SabatierPharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France.
Isabelle BorgetGustave Roussy, Office of Biostatistics and Epidemiology, Université Paris-Saclay, Villejuif, France.ORCID https://orcid.org/0000-0002-6295-6361
Nicolas MartelliPharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France.ORCID https://orcid.org/0000-0001-5959-231X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo better understand the process of hospital acquisition of innovative medical devices (MDs) and the hospital-based health technology assessment (HB-HTA) pathways in France, an in-depth study based on a quantitative approach is needed. The aim of the present study was to assess through a national survey how HB-HTA is currently implemented in French hospitals and to identify its level of formalization.

methodsA quantitative online survey was conducted among hospitals performing HB-HTA in France, with a focus on the acquisition of innovative MDs for individual use. The survey, conducted between March and June 2022, was developed by a scientific board composed of members of the French-speaking Society for HB-HTA.

resultsSixty-seven out of 131 surveyed hospitals with HB-HTA activities responded, including 29 university hospitals, 24 nonprofit private hospitals, and 14 local hospitals. Sixty-one respondents (91 percent) reported the existence of a process dedicated to evaluating innovative MDs; of these, 16 declared that their hospitals had a formalized unit with HB-HTA activity. These units were more frequently found in larger hospitals with more than 500 inpatient beds (n = 16, p = 0.0160) and in university hospitals (n = 12, p = 0.0158). No hospital reported any collaboration with HAS, the French national HTA agency.

conclusionA diverse range of HB-HTA organizations with different structural levels exist in France for MD procurement linked to the category of hospitals. The study highlights the need for recognition of HB-HTA activity at the regulatory level in France and for direct collaboration between HTA activities performed at local and national levels.

Indexed as

PropanolaminesTechnology Assessment, BiomedicalFranceHospitals, UniversityHumansP 0160Propanolamineshospital-based HTAmedical devicesprocurementtherapeutic innovations

Identifiers

PMID37732461
PMCPMC11570185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.